Vitrolife: Another quarter with improved organic growth - Redeye

Vitrolife delivered a consecutive positive organic growth recovery with 7% organic growth in constant currencies (CER), this time without support from unusually large orders. The company is approaching the its targeted organic growth for most of business faster than we expected earlier. Our updated view is a base case valuation of SEK 260 (260), a Bull Case of SEK 400 (400), and a Bear Case of SEK 110 (110).

Länk till analysen i sin helhet: https://www.redeye.se/research/1048767/vitrolife-another-quarter-with-improved-organic-growth?utm_source=finwire&utm_medium=RSS